

SEQUENCE LISTING

<110> AVENTIS PHARMA S.A.

<120> HYBRID PROMOTERS

<130> PPAR INFLAMMATION

<140>

<141>

<160> 7

<170> PatentIn Ver. 2.1

<210> 1

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: PPRE element

<400> 1

caaaactagg tcaaaggcca

20

<210> 2

<211> 38

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: PPRE element

<400> 2

caaaactagg tcaaagggtca aaactagggtc aaagggtca

38

<210> 3

<211> 41

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: PPRE element

<400> 3

caaaactagg tcaaagggtca tcaaaactag gtcaaagggtc a

41

<210> 4

<211> 52

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: PPRE element

<400> 4

caaaactagg tcaaagggtca tgtctttagg cccaaaacta ggtcaaagggt ca

52

<210> 5

<211> 271

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: fragment of the PLA2s promoter

<400> 5

cgcgggcaaaa ctgcctgaaa tgtgttttgg catcagctac tgacacgtaa ggtttcccaa 60
tcctcaactc tgtcctgcca gctgatgagg ggaaggaaag ggattaccta ggggtatggg 120
cgaccaatcc tgagtccacc aactgaccac gcccatcccc agccttgtgc ctcacctacc 180
cccaacctcc cagaggggagc agctatttaa ggggagcagg agtgcagAAC aaacaagacg 240
gcctggggat acaactctgg agtcctctga g 271

<210> 6

<211> 332

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description/PPRE/PLA2s hybrid promoter

<400> 6

gtaccaattc gacaaaacta ggtcaaaggt catcaaaact aggtcaaagg tcaaattcga 60
acgcggcaaaa actgcctgaa atgtgttttg gcatcagcta ctgacacgta aggtttccca 120
atcctcaact ctgtcctgcc agctgatgag gggaaggaaa gggattacct aggggtatgg 180
gcgaccaatc ctgagtccac caactgacca cggccatccc cagccttgtg cctcacctac 240
ccccaacctc ccagagggag cagctattta aggggagcag gagtgcagaa caaacaagac 300
ggcctgggga tacaactctg gagtctctg ag 332

<210> 7

<211> 944

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: sequence conferring specificity of expression

<400> 7

tgcgggctc gcggtgagcc ctgatccgcc tcggggctcc ccagtcgctg gtgctgctga 60
cgctgctcat cgccgcggtc ctacggtgtc agggccagga tgcccgtaag tcgcccgcgc 120
cccctgcta cttccctgac ttgtgacctt ttctctcta ctccctcccc caagtactag 180
gatcccccta gagcttgagc atctgggatt ggcagcgatg gcttcagat gggctgaaac 240
cctgcccgtg tttattttaa ctggttcctc gtggagagct gtgaatcggg ctctgtatgc 300
gcttgagaaa agccccattc atgagaggca agggccagtg ggtcccccaa ctccccgacc 360
cccctctccc acaatgcaca gcctccccgc cctcatcccc cccccacccc ccgtgcccgc 420
ctgcccgcac cttcagatcg atctgggatt ggcagcgatg gcttcagat gggctgaaac 480
cctgcccgtg tttattttaa ctggttcctc gtggagagct gtgaatcggg ctctgtatgc 540
gcttgagaaa agccccattc atgagaggca agggccagtg ggtcccccaa ctccccgacc 600
cccctctccc acaatgcaca gcctccccgc cctcatcccc cccccacccc ccgtgcccgc 660
cctgcccga cctccagatc tccagctaga ggatctgcca ctctagggtt cgaaatcgat 720
aagccaagct ctagtggatc ccccgggctg cagatctgta gggcgagta gtccagggtt 780
tccttgatga tgcatactt atcctgtccc ttttttttcc acagctcgcg gttgaggaca 840
aactcttcgc ggtctttcca gtggggatcg acggtatcga taagcttgat gatctgtgac 900
atggcggatc ccgtcgtttt acaacgtcgt gactgggaaa accc 944